Angiogenic and Fibrinolytic Factors in Blood During the First Half of Pregnancy and Adverse Pregnancy Outcomes
العنوان: | Angiogenic and Fibrinolytic Factors in Blood During the First Half of Pregnancy and Adverse Pregnancy Outcomes |
---|---|
المؤلفون: | Eric A.P. Steegers, Henk Russcher, Marianne Coolman, Jan Lindemans, Fred C.G.J. Sweep, Christianne J.M. de Groot, Vincent V. W. Jaddoe, Albert Hofman, Sarah Timmermans, Anneke Geurts-Moespot |
المساهمون: | Obstetrics & Gynecology, Clinical Chemistry, Epidemiology, Erasmus MC other, Obstetrics and gynaecology, ICaR - Ischemia and repair |
المصدر: | Obstetrics and Gynecology, 119, 6, pp. 1190-200 Obstetrics and Gynecology, 119, 1190-200 Coolman, M, Timmermans, S, de Groot, C J M, Russcher, H, Lindemans, J, Hofman, A, Geurts-Moespot, A J, Sweep, F C G J, Jaddoe, V V W & Steegers, E A P 2012, ' Angiogenic and Fibrinolytic Factors in Blood During the First Half of Pregnancy and Adverse Pregnancy Outcomes ', Obstetrics and Gynecology, vol. 119, no. 6, pp. 1190-1200 . https://doi.org/10.1097/AOG.0b013e318256187f Obstetrics and Gynecology, 119(6), 1190-1200. Lippincott Williams & Wilkins Obstetrics and Gynecology, 119(6), 1190-1200. Lippincott Williams and Wilkins |
بيانات النشر: | Lippincott Williams & Wilkins, 2012. |
سنة النشر: | 2012 |
مصطلحات موضوعية: | Placental growth factor, Adult, Male, medicine.medical_specialty, Birth weight, Placenta, Population, Pregnancy Proteins, Preeclampsia, Young Adult, Pre-Eclampsia, Pregnancy, medicine.artery, Internal medicine, medicine, Plasminogen Activator Inhibitor 2, Humans, Prospective Studies, Uterine artery, education, Placenta Growth Factor, education.field_of_study, Fetal Growth Retardation, Vascular Endothelial Growth Factor Receptor-1, business.industry, Pregnancy Outcome, Obstetrics and Gynecology, Odds ratio, medicine.disease, Pregnancy Trimester, First, Endocrinology, Pregnancy Trimester, Second, Hormonal regulation Aetiology, screening and detection [IGMD 6], Gestation, Female, Vascular Resistance, business, Biomarkers |
الوصف: | Item does not contain fulltext OBJECTIVE: To estimate whether the imbalance of angiogenic factors (soluble fms-like tyrosine kinase-1, placental growth factor) and fibrinolytic factors (plasminogen activator inhibitor-2 [PAI-2]) might affect placentation in early pregnancy. METHODS: We studied the associations of maternal soluble fms-like tyrosine kinase-1, placental growth factor, and PAI-2 concentrations in the first trimester (before 18 weeks of gestation) and soluble fms-like tyrosine kinase-1 and placental growth factor concentrations in the second trimester (18-25 weeks of gestation) with placental function and adverse pregnancy outcomes. This study was embedded in a population-based prospective cohort study. Data were used from 7,519 women. Biomarker concentrations were divided into deciles and evaluated in multivariable linear and logistic regression models. RESULTS: First-trimester high soluble fms-like tyrosine kinase-1 was associated with a 5.2% lower uterine artery index in the second-trimester and a 1.6% higher birth weight (55 g, confidence interval [CI] 15-95). Neither in the first nor in the second trimester were soluble fms-like tyrosine kinase-1 concentrations significantly associated with preeclampsia. First-trimester low placental growth factor was associated with a 6.1% higher uterine artery index and a 3.4% lower birth weight (-115 g, CI -157 to -74). First-trimester low placental growth factor was associated with fetal growth restriction (odds ratio [OR] 2.62, CI 1.68-4.08) and preeclampsia (OR 2.46, CI 1.49-4.08). First-trimester low PAI-2 was associated with a 1.9% higher uterine artery index and a 2.7% lower birth weight (-94 g, CI -136 to -51). First-trimester low PAI-2 was associated with a higher risk of fetal growth restriction (OR 2.22, CI 1.39-3.55). CONCLUSION: First-half-of-pregnancy concentrations of soluble fms-like tyrosine kinase-1, placental growth factor, and PAI-2 are associated with uteroplacental vascular resistance, placental weight, and birth weight. Moreover, first-trimester placental growth factor and PAI-2 are associated with an increased risk of adverse pregnancy outcomes. LEVEL OF EVIDENCE: II. 01 juni 2012 |
تدمد: | 1873-233X 0029-7844 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::819c6bd2388eed028329049b9ba6cc64 https://pure.eur.nl/en/publications/0b99fd59-5b36-4e8b-b84b-dd7de7e3a280 |
حقوق: | RESTRICTED |
رقم الأكسشن: | edsair.doi.dedup.....819c6bd2388eed028329049b9ba6cc64 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 1873233X 00297844 |
---|